Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_assertion type Assertion NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_head.
- NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_assertion description "[In conclusion, the results of the present study demonstrated that PI3K/AKT and Rab25 significantly contributed to cisplatin resistance in human epithelial ovarian cancer; in addition, silencing Rab25 or inhibiting the PI3K/AKT pathway markedly increased the sensitivity of these cells to cisplatin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_provenance.
- NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_assertion evidence source_evidence_literature NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_provenance.
- NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_assertion SIO_000772 25405658 NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_provenance.
- NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_assertion wasDerivedFrom befree-2016 NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_provenance.
- NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_assertion wasGeneratedBy ECO_0000203 NP1238232.RAp68Af4WKiLXSmKxBSAYBEln5_O3V3PCKdsd8NDwY-EM130_provenance.